Telomir Pharmaceuticals, Inc.
TELO
$4.58
-$0.45-8.95%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -26.48% | -442.61% | -580.57% | -1,383.39% | -1,430.30% |
Total Depreciation and Amortization | -- | -- | -- | -- | -- |
Total Amortization of Deferred Charges | 169.20% | 485.65% | 4,598.47% | -- | -- |
Total Other Non-Cash Items | -6.54% | 90,851.85% | 7,486,600.00% | -- | -- |
Change in Net Operating Assets | 10.97% | -84.82% | -173.78% | 161.86% | -70.45% |
Cash from Operations | -31.36% | -83.32% | -491.67% | -344.52% | -723.69% |
Capital Expenditure | -- | -- | -- | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -- | -- | -- | -- | -- |
Total Debt Issued | -100.00% | -53.48% | 240.29% | 693.18% | 573.79% |
Total Debt Repaid | -- | -211.46% | -- | -- | -- |
Issuance of Common Stock | 530.30% | 461.42% | 461.42% | 461.42% | 1,881.82% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 100.00% | -94.75% | 75.84% | -64.40% | -441.23% |
Cash from Financing | 64.14% | 111.08% | 656.42% | 633.42% | 721.02% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 632,550.00% | 21,438.46% | 31,583.05% | 131,000.00% | -113.33% |